BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 32546838)

  • 1. Chemogenomic profiling of breast cancer patient-derived xenografts reveals targetable vulnerabilities for difficult-to-treat tumors.
    Savage P; Pacis A; Kuasne H; Liu L; Lai D; Wan A; Dankner M; Martinez C; Muñoz-Ramos V; Pilon V; Monast A; Zhao H; Souleimanova M; Annis MG; Aguilar-Mahecha A; Lafleur J; Bertos NR; Asselah J; Bouganim N; Petrecca K; Siegel PM; Omeroglu A; Shah SP; Aparicio S; Basik M; Meterissian S; Park M
    Commun Biol; 2020 Jun; 3(1):310. PubMed ID: 32546838
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of Personalized Therapeutic Strategies by Targeting Actionable Vulnerabilities in Metastatic and Chemotherapy-Resistant Breast Cancer PDXs.
    Punzi S; Meliksetian M; Riva L; Marocchi F; Pruneri G; Criscitiello C; Orsi F; Spaggiari L; Casiraghi M; Della Vigna P; Luzi L; Curigliano G; Pelicci PG; Lanfrancone L
    Cells; 2019 Jun; 8(6):. PubMed ID: 31216647
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor Sequencing and Patient-Derived Xenografts in the Neoadjuvant Treatment of Breast Cancer.
    Goetz MP; Kalari KR; Suman VJ; Moyer AM; Yu J; Visscher DW; Dockter TJ; Vedell PT; Sinnwell JP; Tang X; Thompson KJ; McLaughlin SA; Moreno-Aspitia A; Copland JA; Northfelt DW; Gray RJ; Hunt K; Conners A; Sicotte H; Eckel-Passow JE; Kocher JP; Ingle JN; Ellingson MS; McDonough M; Wieben ED; Weinshilboum R; Wang L; Boughey JC
    J Natl Cancer Inst; 2017 Jul; 109(7):. PubMed ID: 28376176
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transcriptome Characterization of Matched Primary Breast and Brain Metastatic Tumors to Detect Novel Actionable Targets.
    Varešlija D; Priedigkeit N; Fagan A; Purcell S; Cosgrove N; O'Halloran PJ; Ward E; Cocchiglia S; Hartmaier R; Castro CA; Zhu L; Tseng GC; Lucas PC; Puhalla SL; Brufsky AM; Hamilton RL; Mathew A; Leone JP; Basudan A; Hudson L; Dwyer R; Das S; O'Connor DP; Buckley PG; Farrell M; Hill ADK; Oesterreich S; Lee AV; Young LS
    J Natl Cancer Inst; 2019 Apr; 111(4):388-398. PubMed ID: 29961873
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of patient-derived tumor xenografts (PDXs) as models for estrogen receptor positive (ER+HER2- and ER+HER2+) breast cancers.
    Kanaya N; Somlo G; Wu J; Frankel P; Kai M; Liu X; Wu SV; Nguyen D; Chan N; Hsieh MY; Kirschenbaum M; Kruper L; Vito C; Badie B; Yim JH; Yuan Y; Hurria A; Peiguo C; Mortimer J; Chen S
    J Steroid Biochem Mol Biol; 2017 Jun; 170():65-74. PubMed ID: 27154416
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Population of Heterogeneous Breast Cancer Patient-Derived Xenografts Demonstrate Broad Activity of PARP Inhibitor in BRCA1/2 Wild-Type Tumors.
    Evans KW; Yuca E; Akcakanat A; Scott SM; Arango NP; Zheng X; Chen K; Tapia C; Tarco E; Eterovic AK; Black DM; Litton JK; Yap TA; Tripathy D; Mills GB; Meric-Bernstam F
    Clin Cancer Res; 2017 Nov; 23(21):6468-6477. PubMed ID: 29093017
    [No Abstract]   [Full Text] [Related]  

  • 7. Molecular heterogeneity of non-small cell lung carcinoma patient-derived xenografts closely reflect their primary tumors.
    Wang D; Pham NA; Tong J; Sakashita S; Allo G; Kim L; Yanagawa N; Raghavan V; Wei Y; To C; Trinh QM; Starmans MH; Chan-Seng-Yue MA; Chadwick D; Li L; Zhu CQ; Liu N; Li M; Lee S; Ignatchenko V; Strumpf D; Taylor P; Moghal N; Liu G; Boutros PC; Kislinger T; Pintilie M; Jurisica I; Shepherd FA; McPherson JD; Muthuswamy L; Moran MF; Tsao MS
    Int J Cancer; 2017 Feb; 140(3):662-673. PubMed ID: 27750381
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Altered Transcriptome and DNA Methylation Profiles of Docetaxel Resistance in Breast Cancer PDX Models.
    Gómez-Miragaya J; Morán S; Calleja-Cervantes ME; Collado-Sole A; Paré L; Gómez A; Serra V; Dobrolecki LE; Lewis MT; Diaz-Lagares A; Eroles P; Prat A; Esteller M; González-Suárez E
    Mol Cancer Res; 2019 Oct; 17(10):2063-2076. PubMed ID: 31320385
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Establishment of a platform of non-small-cell lung cancer patient-derived xenografts with clinical and genomic annotation.
    Kang HN; Choi JW; Shim HS; Kim J; Kim DJ; Lee CY; Hong MH; Park SY; Park AY; Shin EJ; Lee SY; Pyo KH; Yun MR; Choi HM; Lee SS; Kim SY; Lee H; Paik S; Cho BC; Lee JG; Kim HR
    Lung Cancer; 2018 Oct; 124():168-178. PubMed ID: 30268457
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Breast tumor PDXs are genetically plastic and correspond to a subset of aggressive cancers prone to relapse.
    du Manoir S; Orsetti B; Bras-Gonçalves R; Nguyen TT; Lasorsa L; Boissière F; Massemin B; Colombo PE; Bibeau F; Jacot W; Theillet C
    Mol Oncol; 2014 Mar; 8(2):431-43. PubMed ID: 24394560
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genome-wide methylation profiling of ovarian cancer patient-derived xenografts treated with the demethylating agent decitabine identifies novel epigenetically regulated genes and pathways.
    Tomar T; de Jong S; Alkema NG; Hoekman RL; Meersma GJ; Klip HG; van der Zee AG; Wisman GB
    Genome Med; 2016 Oct; 8(1):107. PubMed ID: 27765068
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Transcriptionally Definable Subgroup of Triple-Negative Breast and Ovarian Cancer Samples Shows Sensitivity to HSP90 Inhibition.
    Shee K; Wells JD; Ung M; Hampsch RA; Traphagen NA; Yang W; Liu SC; Zeldenrust MA; Wang L; Kalari KR; Yu J; Boughey JC; Demidenko E; Kettenbach AN; Cheng C; Goetz MP; Miller TW
    Clin Cancer Res; 2020 Jan; 26(1):159-170. PubMed ID: 31558472
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecularly annotation of mouse avatar models derived from patients with colorectal cancer liver metastasis.
    Wang J; Xing B; Liu W; Li J; Wang X; Li J; Yang J; Ji C; Li Z; Dong B; Gao J; Shen L
    Theranostics; 2019; 9(12):3485-3500. PubMed ID: 31281492
    [No Abstract]   [Full Text] [Related]  

  • 14. Tumor xenograft modeling identifies an association between TCF4 loss and breast cancer chemoresistance.
    Ruiz de Garibay G; Mateo F; Stradella A; Valdés-Mas R; Palomero L; Serra-Musach J; Puente DA; Díaz-Navarro A; Vargas-Parra G; Tornero E; Morilla I; Farré L; Martinez-Iniesta M; Herranz C; McCormack E; Vidal A; Petit A; Soler T; Lázaro C; Puente XS; Villanueva A; Pujana MA
    Dis Model Mech; 2018 May; 11(5):. PubMed ID: 29666142
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of anti-PD-1-based therapy against triple-negative breast cancer patient-derived xenograft tumors engrafted in humanized mouse models.
    Rosato RR; Dávila-González D; Choi DS; Qian W; Chen W; Kozielski AJ; Wong H; Dave B; Chang JC
    Breast Cancer Res; 2018 Sep; 20(1):108. PubMed ID: 30185216
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of PI3K and MEK inhibitors yields durable remission in PDX models of PIK3CA-mutated metaplastic breast cancers.
    Coussy F; El Botty R; Lavigne M; Gu C; Fuhrmann L; Briaux A; de Koning L; Dahmani A; Montaudon E; Morisset L; Huguet L; Sourd L; Painsec P; Chateau-Joubert S; Larcher T; Vacher S; Melaabi S; Salomon AV; Marangoni E; Bieche I
    J Hematol Oncol; 2020 Feb; 13(1):13. PubMed ID: 32087759
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient-derived xenografts from non-small cell lung cancer brain metastases are valuable translational platforms for the development of personalized targeted therapy.
    Lee HW; Lee JI; Lee SJ; Cho HJ; Song HJ; Jeong DE; Seo YJ; Shin S; Joung JG; Kwon YJ; Choi YL; Park WY; Lee HM; Seol HJ; Shim YM; Joo KM; Nam DH
    Clin Cancer Res; 2015 Mar; 21(5):1172-82. PubMed ID: 25549722
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Separation of breast cancer and organ microenvironment transcriptomes in metastases.
    Alzubi MA; Turner TH; Olex AL; Sohal SS; Tobin NP; Recio SG; Bergh J; Hatschek T; Parker JS; Sartorius CA; Perou CM; Dozmorov MG; Harrell JC
    Breast Cancer Res; 2019 Mar; 21(1):36. PubMed ID: 30841919
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Proof of Concept for Biomarker-Guided Targeted Therapy against Ovarian Cancer Based on Patient-Derived Tumor Xenografts.
    Palmer AC; Plana D; Gao H; Korn JM; Yang G; Green J; Zhang X; Velazquez R; McLaughlin ME; Ruddy DA; Kowal C; Muszynski J; Bullock C; Rivera S; Rakiec DP; Elliott G; Fordjour P; Meyer R; Loo A; Kurth E; Engelman JA; Bitter H; Sellers WR; Williams JA; Sorger PK
    Cancer Res; 2020 Oct; 80(19):4278-4287. PubMed ID: 32747364
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patient-Derived Xenografts from Solid Tumors (PDX) for Models of Metastasis.
    Wulf-Goldenberg A; Hoffmann J; Becker M; Brzezicha B; Walther W
    Methods Mol Biol; 2021; 2294():43-58. PubMed ID: 33742393
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.